Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 45Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 3Adenocarcinoma 3Resectable Pancreatic Cancer 2Rectal Neoplasms 2Pancreatic Cancer Metastatic 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Stomach Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Neoplasms, Basal Cell 1Locally Advanced Pancreatic Adenocarcinoma 1Localized Pancreatic Adenocarcinoma 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma 1Borderline Resectable Pancreatic Cancer 1

Interventions

Trastuzumab 2Oxaliplatin 2Melphalan 2Leucovorin 2tipifarnib 1napabucasin 1irinotecan sucrosofate 1folfirinox 1Temozolomide 1Taxes 1Sunitinib 1Paclitaxel 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Fluorouracil 1Floxuridine 1Filgrastim 1Fentanyl 1Everolimus 1Cytokines 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × folfirinox × Gastrointestinal × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡